振东制药拟斥资不超10亿元自有资金进行现金管理

Core Viewpoint - Shanxi Zhendong Pharmaceutical Co., Ltd. has announced the use of its own funds for cash management, with a maximum investment of RMB 1 billion, aimed at improving fund utilization efficiency while ensuring normal operations and liquidity [1][2]. Group 1: Cash Management Details - The purpose of the investment is to enhance fund utilization efficiency without affecting normal operations and ensuring fund safety [2]. - The company plans to invest in low to medium-risk financial products issued by banks, securities firms, trust companies, and asset management companies, excluding high-risk investment types [2]. - The resolution is valid for one year from the date of approval by the board [2]. - The management is authorized to implement the cash management within the specified limit [2]. Group 2: Risk Management Measures - The company will adhere to prudent investment principles, selecting low to medium-risk investment products, with the finance department monitoring progress and addressing risks promptly [3]. - The supervisory department will audit and supervise the use and custody of funds for investment products, estimating potential returns and losses [3]. - The supervisory board has the authority to oversee the use of funds and may hire professional institutions for auditing if necessary [3]. Group 3: Board and Supervisory Approval - The proposal received approval from both the board and the supervisory board, which deemed it beneficial for improving fund utilization efficiency and cash management returns, aligning with the interests of the company and all shareholders [3].